The deputy director of the Spanish Biosimilar Medicines Association (BioSim), Isabel del Río, comments on the current status of biosimilars in Spain – including the nearly EUR one billion in savings they bring to the system – the most important elements included in the upcoming national plan to promote the use of biosimilars, and explains how gainsharing agreements could further improve the uptake of these medicines.
We have observed big improvements in terms of trust [in biosimilars] from both healthcare professionals and patients [in Spain] in the last few years
